CN1056373C - 含氮杂环类化合物的氟代烷氧基苄氨基衍生物的制备方法 - Google Patents

含氮杂环类化合物的氟代烷氧基苄氨基衍生物的制备方法 Download PDF

Info

Publication number
CN1056373C
CN1056373C CN92104778A CN92104778A CN1056373C CN 1056373 C CN1056373 C CN 1056373C CN 92104778 A CN92104778 A CN 92104778A CN 92104778 A CN92104778 A CN 92104778A CN 1056373 C CN1056373 C CN 1056373C
Authority
CN
China
Prior art keywords
formula
compound
group
phenyl
trifluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92104778A
Other languages
English (en)
Chinese (zh)
Other versions
CN1067655A (zh
Inventor
J·A·洛
T·J·罗森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1067655A publication Critical patent/CN1067655A/zh
Application granted granted Critical
Publication of CN1056373C publication Critical patent/CN1056373C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
    • C07C45/513—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being an etherified hydroxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN92104778A 1991-06-20 1992-06-19 含氮杂环类化合物的氟代烷氧基苄氨基衍生物的制备方法 Expired - Fee Related CN1056373C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71794391A 1991-06-20 1991-06-20
US717,943 1991-06-20

Publications (2)

Publication Number Publication Date
CN1067655A CN1067655A (zh) 1993-01-06
CN1056373C true CN1056373C (zh) 2000-09-13

Family

ID=24884155

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92104778A Expired - Fee Related CN1056373C (zh) 1991-06-20 1992-06-19 含氮杂环类化合物的氟代烷氧基苄氨基衍生物的制备方法

Country Status (31)

Country Link
US (3) US5773450A (enExample)
EP (1) EP0589924B1 (enExample)
JP (1) JPH07110850B2 (enExample)
KR (1) KR0154882B1 (enExample)
CN (1) CN1056373C (enExample)
AT (1) ATE142199T1 (enExample)
AU (1) AU657967B2 (enExample)
BR (2) BR9206161A (enExample)
CA (1) CA2109613C (enExample)
CZ (1) CZ290475B6 (enExample)
DE (2) DE9290083U1 (enExample)
DK (1) DK0589924T3 (enExample)
EG (1) EG20280A (enExample)
ES (1) ES2092113T3 (enExample)
FI (3) FI990419A7 (enExample)
GR (1) GR3021411T3 (enExample)
HU (2) HU224443B1 (enExample)
IE (1) IE921986A1 (enExample)
IL (1) IL102188A (enExample)
MX (1) MX9203018A (enExample)
NO (1) NO180715C (enExample)
NZ (1) NZ243230A (enExample)
PL (2) PL172054B1 (enExample)
PT (1) PT100606B (enExample)
RU (1) RU2114848C1 (enExample)
SK (1) SK282203B6 (enExample)
TW (1) TW201301B (enExample)
UA (1) UA39168C2 (enExample)
WO (1) WO1993000331A1 (enExample)
YU (1) YU48997B (enExample)
ZA (1) ZA924528B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
FI990419A7 (fi) * 1991-06-20 1999-02-26 Pfizer Typpeä sisältävien hetrosyklisten yhdisteiden fluorialkoksibentsyyliaminojohdannaiset
DE69231395T3 (de) 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
EP0641328B1 (en) * 1992-05-18 2001-11-21 Pfizer Inc. Bridged aza-bicyclic derivatives as substance p antagonists
AU4396193A (en) * 1992-08-04 1994-03-03 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
ATE208376T1 (de) * 1992-08-19 2001-11-15 Pfizer Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
FR2700472B1 (fr) 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
DK0700384T3 (da) * 1993-05-28 1997-12-08 Pfizer fremgangsmåde til fremstilling og opløsning af 2-phenyl-3-aminopiperidin
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
WO1995007886A1 (en) * 1993-09-17 1995-03-23 Pfizer Inc. 3-amino-5-carboxy-substituted piperidines and 3-amino-4-carboxy-substituted pyrrolidines as tachykinin antagonists
AU7082194A (en) * 1993-09-17 1995-04-03 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists to inhibit angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
EP0802912B1 (en) * 1995-01-12 2004-10-13 Glaxo Group Limited Piperidine derivatives having tachykinin antagonist activity
GB9505692D0 (en) * 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
ATE182788T1 (de) 1995-10-10 1999-08-15 Pfizer Nk-1 rezeptor antagonisten in neurogener entzündung in gen-therapie
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
PT780375E (pt) 1995-12-21 2002-12-31 Pfizer 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
KR19990030614A (ko) * 1997-10-02 1999-05-06 성재갑 스쿠알렌 합성 효소 억제활성을 갖는 신규 화합물, 그의 제조방법 및 그를 포함하는 조성물
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
SK252004A3 (sk) * 2001-07-20 2005-03-04 Pfizer Products Inc. Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
TWI410650B (zh) * 2007-11-09 2013-10-01 Hon Hai Prec Ind Co Ltd 轉接板
AU2009222122A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005729A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine therapeutic agents
WO1991018899A1 (en) * 1990-06-01 1991-12-12 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
WO1992001688A1 (en) * 1990-07-23 1992-02-06 Pfizer Inc. Quinuclidine derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452026A (en) * 1966-03-15 1969-06-24 Bristol Myers Co Substituted 1,2,3,4-tetrahydroquinolines
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
HUT68667A (en) * 1990-09-28 1995-07-28 Pfizer Fused ring analogs of nitrogen containing nonaromatic heterocycles
EP0552197B1 (en) * 1990-10-03 1999-01-13 Commonwealth Scientific And Industrial Research Organisation Epoxy resins based on diaminobisimide compounds
US5138060A (en) * 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
SK284565B6 (sk) * 1991-03-26 2005-06-02 Pfizer Inc. Spôsob prípravy substituovaných piperidínov
PL171921B1 (pl) * 1991-05-22 1997-06-30 Pfizer Sposób wytwarzania nowych pochodnych podstawionej 3-aminochinuklidyny PL PL PL PL PL
UA27776C2 (uk) * 1991-05-31 2000-10-16 Пфайзер Інк. Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
FI990419A7 (fi) * 1991-06-20 1999-02-26 Pfizer Typpeä sisältävien hetrosyklisten yhdisteiden fluorialkoksibentsyyliaminojohdannaiset
AU4396193A (en) * 1992-08-04 1994-03-03 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005729A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine therapeutic agents
WO1991018899A1 (en) * 1990-06-01 1991-12-12 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
WO1992001688A1 (en) * 1990-07-23 1992-02-06 Pfizer Inc. Quinuclidine derivatives

Also Published As

Publication number Publication date
SK282203B6 (sk) 2001-12-03
NO934691L (no) 1993-12-17
YU48997B (sh) 2003-04-30
FI990418A0 (fi) 1999-02-26
HU221634B1 (hu) 2002-12-28
WO1993000331A1 (en) 1993-01-07
CN1067655A (zh) 1993-01-06
DE69213451T2 (de) 1997-01-09
JPH07110850B2 (ja) 1995-11-29
KR940701383A (ko) 1994-05-28
HK1000247A1 (en) 1998-02-13
HU9303668D0 (en) 1994-04-28
DK0589924T3 (da) 1996-09-30
ES2092113T3 (es) 1996-11-16
FI990418L (fi) 1999-02-26
NO180715C (no) 1997-06-04
RU2114848C1 (ru) 1998-07-10
KR0154882B1 (ko) 1998-11-16
US5773450A (en) 1998-06-30
YU64092A (sh) 1995-03-27
CZ290475B6 (cs) 2002-07-17
HU224443B1 (hu) 2005-09-28
HUT70499A (en) 1995-10-30
PT100606A (pt) 1993-08-31
US5744480A (en) 1998-04-28
BR1100086A (pt) 2000-07-25
JPH06506473A (ja) 1994-07-21
PL170516B1 (en) 1996-12-31
IL102188A0 (en) 1993-01-14
AU657967B2 (en) 1995-03-30
CZ390892A3 (en) 1994-04-13
FI990419L (fi) 1999-02-26
DE69213451D1 (de) 1996-10-10
CA2109613A1 (en) 1993-01-07
DE9290083U1 (de) 1994-02-17
ZA924528B (en) 1993-12-20
IE921986A1 (en) 1992-12-30
FI935701L (fi) 1993-12-17
FI108794B (fi) 2002-03-28
HUT67434A (en) 1995-04-28
EP0589924B1 (en) 1996-09-04
FI110686B (fi) 2003-03-14
PT100606B (pt) 1999-10-29
FI990419A0 (fi) 1999-02-26
NO934691D0 (no) 1993-12-17
GR3021411T3 (en) 1997-01-31
IL102188A (en) 2002-12-01
FI990419A7 (fi) 1999-02-26
TW201301B (enExample) 1993-03-01
HU9500836D0 (en) 1995-05-29
ATE142199T1 (de) 1996-09-15
NZ243230A (en) 1997-06-24
SK390892A3 (en) 1995-09-13
MX9203018A (es) 1993-07-01
US20030199540A1 (en) 2003-10-23
FI935701A0 (fi) 1993-12-17
NO180715B (no) 1997-02-24
BR9206161A (pt) 1995-10-31
EG20280A (en) 1998-07-30
PL172054B1 (pl) 1997-07-31
CA2109613C (en) 1996-11-19
EP0589924A1 (en) 1994-04-06
AU1889392A (en) 1993-01-25
UA39168C2 (uk) 2001-06-15

Similar Documents

Publication Publication Date Title
CN1056373C (zh) 含氮杂环类化合物的氟代烷氧基苄氨基衍生物的制备方法
CN1036652C (zh) 碱式季酰胺，其制备方法及其药物组合物
CN1090188C (zh) 新的苯并萘啶类化合物
CN1064356C (zh) 新哌嗪、哌啶与1,2,5,6－四氢吡啶化合物，其制法及其药物组合物
CN1060285A (zh) 含氮非芳香杂环的稠环类似物
CN1191862A (zh) 8－取代的1,3,8－三氮杂螺[4.5]癸烷－4－酮衍生物
CN1092771A (zh) 氨基亚甲基取代的非芳香杂环化合物
CN1294577A (zh) 钾通道抑制剂
CN1058405A (zh) 奎宁环衍生物
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法
CN1042133C (zh) N－取代的氮杂双环庚烷衍生物及其用途
CN1222521A (zh) 1,3,8－三氮杂螺[4,5]癸－4－酮衍生物
CN1226825A (zh) 胺化合物用于制备阻止肿瘤细胞增殖的药物
CN1071755C (zh) 杂环甲酰胺衍生物及其作为治疗剂的用途
CN100338074C (zh) 杂环化合物和以其为有效成分的脑机能改善剂
CN1049658C (zh) 吡唑并[４，３－ｃ]吡啶，它们的制备方法及其作为５－羟色胺再摄入抑制剂的用途
CN1166833A (zh) 嘧啶基吡唑衍生物
CN1024663C (zh) 治疗气喘用的取代的四氢化萘类化合物的制备方法
CN1041088C (zh) 光学活性咪唑烷酮衍生物和抗痴呆药物组合物
CN1179962C (zh) 氮杂吲哚嗪酮衍生物和以其为有效成分的脑功能改善剂
CN87104641A (zh) 4-(芳酰氨基)哌啶丁酰氨衍生物
CN1281607C (zh) 具有镇痛作用的新型单哌嗪季铵盐类化合物
CN1135215A (zh) 咪唑啉酮衍生物、其酸的加成盐及老年痴呆症的治疗药物
CN1028531C (zh) 1-氧杂-2-氧代-8-氮杂螺[4，5]癸烷衍生物及其盐的制备方法
CN87106267A (zh) 新化合物2，3，4，5，6，7-六氢-2，7-亚甲基-1，5-苯并唑宁和-1，4-苯并唑宁，其制备方法及其药物组合物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20000913